{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:20:07Z","timestamp":1773332407602,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12325-023-02520-2","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T17:02:01Z","timestamp":1685984521000},"page":"2985-3005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular Atrophy"],"prefix":"10.1007","volume":"40","author":[{"given":"Tammy","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bora","family":"Youn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela D.","family":"Paradis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Beckerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianne","family":"Barnieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"6","key":"2520_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"10","key":"2520_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345.","journal-title":"Pharmacoeconomics"},{"key":"2520_CR3","unstructured":"Phillippo DM, Ades AE, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. 2016.\nhttps:\/\/www.sheffield.ac.uk\/nicedsu\/tsds\/population-adjusted"},{"issue":"6","key":"2520_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40273-015-0271-1","volume":"33","author":"KJ Ishak","year":"2015","unstructured":"Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537\u201349.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"2520_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2165\/11537420-000000000-00000","volume":"28","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, Ishak KJ. No head-to-head trial? simulate the missing arms. Pharmacoeconomics. 2010;28(10):957\u201367.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2520_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2018;38(2):200\u201311.","journal-title":"Med Decis Mak"},{"issue":"4","key":"2520_CR7","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1214\/20-AOAS1359","volume":"14","author":"D Cheng","year":"2020","unstructured":"Cheng D, Ayyagari R, Signorovitch J. The statistical performance of matching-adjusted indirect comparisons: estimating treatment effects with aggregate external control data. Ann Appl Stat. 2020;14(4):1806\u201333.","journal-title":"Ann Appl Stat"},{"key":"2520_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","volume":"28","author":"J Kirschner","year":"2020","unstructured":"Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38\u201343.","journal-title":"Eur J Paediatr Neurol"},{"key":"2520_CR9","doi-asserted-by":"crossref","unstructured":"Darras BT, Markowitz JA, Monani UR, et al. Spinal muscular atrophies. In: Darras BT, Jones HR, Ryan MM, et al., editors. Neuromuscular disorders of infancy, childhood, and adolescence: a clinician\u2019s approach. San Diego: Academic; 2015.","DOI":"10.1016\/B978-0-12-417044-5.00008-1"},{"key":"2520_CR10","unstructured":"Food and Drug Administration. SPINRAZA (nusinersen) injection, for intrathecal use 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf. Accessed 22 Sep 2022."},{"key":"2520_CR11","unstructured":"European Medicines Agency. SPINRAZA (nusinersen) EMEA\/H\/C\/004312 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza. Accessed 22 Sep 2022."},{"key":"2520_CR12","unstructured":"Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension for intravenous infusion 2021. https:\/\/www.fda.gov\/media\/126109\/download. Accessed 22 Sep 2022."},{"key":"2520_CR13","unstructured":"European Medicines Agency. ZOLGENSMA (onasemnogene abeparvovec) EMEA\/H\/C\/004750 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma. Accessed 22 Sep 2022."},{"key":"2520_CR14","unstructured":"Food and Drug Administration. EVRYSDI (risdiplam) for oral solution 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213535s003s005lbl.pdf. Accessed 22 Sep 2022."},{"key":"2520_CR15","unstructured":"European Medicines Agency. EVRYSDI (risdiplam) EMEA\/H\/C\/005145 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi. Accessed 22 Sep 2022."},{"issue":"4","key":"2520_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417\u201328.","journal-title":"Value Health"},{"issue":"4","key":"2520_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429\u201337.","journal-title":"Value Health"},{"issue":"1","key":"2520_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2217\/cer.13.84","volume":"3","author":"D Alemayehu","year":"2014","unstructured":"Alemayehu D, Cappelleri JC. Evaluating methodological assumptions in comparative effectiveness research: overcoming pitfalls. J Comp Eff Res. 2014;3(1):79\u201393.","journal-title":"J Comp Eff Res"},{"issue":"7","key":"2520_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1080\/03007995.2020.1747998","volume":"36","author":"IA Samjoo","year":"2020","unstructured":"Samjoo IA, Worthington E, Haltner A, et al. The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. Curr Med Res Opin. 2020;36(7):1145\u201356.","journal-title":"Curr Med Res Opin"},{"key":"2520_CR20","unstructured":"Liao S, Bohn J, de Moor C, et al., editors. A cautionary tale for indirect treatment comparisons: an example from infantile-onset spinal muscular atrophy. In: Virtual ISPOR Europe; 2020. https:\/\/www.valueinhealthjournal.com\/article\/S1098-3015(20)34101-2\/pdf"},{"issue":"10","key":"2520_CR21","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","volume":"37","author":"M Bischof","year":"2021","unstructured":"Bischof M, Lorenzi M, Lee J, et al. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr Med Res Opin. 2021;37(10):1719\u201330.","journal-title":"Curr Med Res Opin"},{"key":"2520_CR22","doi-asserted-by":"crossref","unstructured":"Ribero VA, Daigl M, Mart\u00ed Y, et al. How does risdiplam compare with other treatments for types 1\u20133 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. J Comp Eff Res. 2022;11(5):347\u201370.","DOI":"10.2217\/cer-2021-0216"},{"key":"2520_CR23","doi-asserted-by":"crossref","unstructured":"Pechmann A, Behrens M, D\u00f6rnbrack K, et al. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain.  2023;146(2):668\u201377.","DOI":"10.1093\/brain\/awac252"},{"issue":"10","key":"2520_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"2520_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Beldzinska M, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385(5):427\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"2520_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JND-200533","volume":"8","author":"MR de Holanda","year":"2021","unstructured":"de Holanda MR, Jorge Polido G, Ciro M, et al. Clinical outcomes in patients with spinal muscular atrophy type 1 treated with nusinersen. J Neuromuscul Dis. 2021;8(2):217\u201324.","journal-title":"J Neuromuscul Dis"},{"key":"2520_CR27","doi-asserted-by":"publisher","unstructured":"CADTH Reimbursement Review. Risdiplam (Evrysdi). Can J Health Technol. 2021;1(11). https:\/\/doi.org\/10.51731\/cjht.2021.185.","DOI":"10.51731\/cjht.2021.185"},{"key":"2520_CR28","unstructured":"Institut National d\u2019Excellence en Sant\u00e9 et en Services Sociaux. EVRYSDI: amyotrophie spinale 5q 2021. https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Juillet_2021\/Evrysdi_2021_06.pdf. Accessed  4 Nov 2022."},{"key":"2520_CR29","doi-asserted-by":"crossref","unstructured":"CADTH Reimbursement Review. Onasemnogene abeparvovec (Zolgensma). Can J Health Technol. 2021;1(9).","DOI":"10.51731\/cjht.2021.167"},{"key":"2520_CR30","unstructured":"Institut National d\u2019Excellence en Sant\u00e9 et en Services Sociaux. ZOLGENSMA: amyotrophie spinale 5q 2020. https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Janvier_2021\/Zolgensma_2020_12.pdf. Accessed  4 Nov 2022."},{"key":"2520_CR31","unstructured":"Haute Authorit\u00e9 de Sant\u00e9. Commission de la Transparence: risdiplam 2021. https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-19266_EVRYSDI_PIC_AVIS%20DEF_CT19266.pdf. Accessed  4 Nov 2022."},{"key":"2520_CR32","unstructured":"Haute Authorit\u00e9 de Sant\u00e9. Commission de la Transparence: onasemnogene abeparvovec 2020. https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-18743_ZOLGENSMA_PIC_INS_AvisDef_CT18743.pdf. Accessed  4 Nov 2022."},{"key":"2520_CR33","unstructured":"Scottish Medicines Consortium. risdiplam 0.75mg\/mL powder for oral solution (Evrysdi) 2021. https:\/\/www.scottishmedicines.org.uk\/media\/6669\/risdiplam-evrysdi-final-jan-2022-amended-270122-for-website.pdf. Accessed  4 Nov 2022."},{"key":"2520_CR34","unstructured":"Scottish Medicines Consortium. onasemnogene abeparvoved 2 \u00d7 10(13) vector genomes\/mL solution for infusion (Zolgensma) 2021. https:\/\/www.scottishmedicines.org.uk\/media\/5813\/onasemnogene-abeparvovec-zolgensma-final-feb-2021-amended-010321docx-for-website.pdf. Accessed  4 Nov 2022."},{"key":"2520_CR35","unstructured":"ClinicalTrials.gov. A study to assess the efficacy and safety of nusinersen (ISIS 396443) in infants with spinal muscular atrophy (ENDEAR). Identifier: NCT02193074. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02193074. Accessed 23 Mar 2022."},{"key":"2520_CR36","unstructured":"ClinicalTrials.gov. A study for participants with spinal muscular atrophy (SMA) who previously participated in nusinersen (ISIS 396443) investigational studies (SHINE). Identifier: NCT02594124. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02594124. Accessed 23 Mar 2022."},{"key":"2520_CR37","unstructured":"ClinicalTrials.gov. Gene replacement therapy clinical trial for participants with spinal muscular atrophy Type 1 (STR1VE). Identifier: NCT03306277. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03306277. Accessed 23 Mar 2022."},{"key":"2520_CR38","unstructured":"ClinicalTrials.gov. Gene transfer clinical trial for spinal muscular atrophy Type 1. Identifier: NCT02122952. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02122952. Accessed 23 Mar 2022."},{"key":"2520_CR39","unstructured":"ClinicalTrials.gov. Investigate safety, tolerability, PK, PD and efficacy of risdiplam (RO7034067) in infants with Type 1 spinal muscular atrophy (FIREFISH). Identifier: NCT02913482. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02913482?id=NCT02913482&draw=2&rank=1&load=cart. Accessed 23 Mar 2022."},{"key":"2520_CR40","unstructured":"ClinicalTrials.gov. A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later-onset spinal muscular atrophy (SMA) (CHERISH). Identifier: NCT02292537. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02292537. Accessed 23 Mar 2022."},{"key":"2520_CR41","unstructured":"ClinicalTrials.gov. A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of risdiplam (RO7034067) in Type 2 and 3 spinal muscular atrophy (SMA) participants (SUNFISH). Identifier: NCT02908685. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02908685. Accessed 23 Mar 2022."},{"issue":"1","key":"2520_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352.","journal-title":"Lancet Neurol"},{"issue":"2 Pt 1","key":"2520_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0022-3476(99)70016-8","volume":"135","author":"L Haataja","year":"1999","unstructured":"Haataja L, Mercuri E, Regev R, et al. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatr. 1999;135(2 Pt 1):153\u201361.","journal-title":"J Pediatr"},{"issue":"1","key":"2520_CR44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/mus.25705","volume":"57","author":"KM Bishop","year":"2018","unstructured":"Bishop KM, Montes J, Finkel RS. Motor milestone assessment of infants with spinal muscular atrophy using the Hammersmith infant neurological exam-part 2: experience from a nusinersen clinical study. Muscle Nerve. 2018;57(1):142\u20136.","journal-title":"Muscle Nerve"},{"issue":"3","key":"2520_CR45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, et al. The Children\u2019s Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20(3):155\u201361.","journal-title":"Neuromuscul Disord"},{"key":"2520_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/B978-0-12-374177-6.10002-9","volume-title":"Bayley-III clinical use and interpretation","author":"KH Armstrong","year":"2010","unstructured":"Armstrong KH, Agazzi HC. Chapter 2\u2014The Bayley-III cognitive scale. In: Weiss LG, Oakland T, Aylward GP, editors. Bayley-III clinical use and interpretation. San Diego: Academic; 2010. p. 29\u201345."},{"issue":"9\u201310","key":"2520_CR47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O'Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord. 2007;17(9\u201310):693\u20137.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"2520_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012140","volume":"5","author":"KJ Swoboda","year":"2010","unstructured":"Swoboda KJ, Scott CB, Crawford TO, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS ONE. 2010;5(8): e12140.","journal-title":"PLoS ONE"},{"issue":"6","key":"2520_CR49","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55(6):869\u201374.","journal-title":"Muscle Nerve"},{"issue":"7","key":"2520_CR50","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02520-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02520-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02520-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:18:40Z","timestamp":1686806320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02520-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2520"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02520-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"15 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}